Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Vericiguat holds promise for heart failure

Dec. 1, 2015

Bayer Schering Pharma divulges sGC activators

Nov. 30, 2015

Fibroblast activation inhibitor preserves cardiac function after heart failure in animal model

Nov. 30, 2015

Bayer Schering Pharma divulges sGC activators

Nov. 27, 2015

Ubenimex receives FDA orphan drug designation for the treatment of PAH

Nov. 27, 2015

FDA grants orphan drug designation to PhaseBio's vasomera

Nov. 27, 2015

Entresto receives E.U. approval

Nov. 25, 2015

Recardio secures financing to advance dutogliptin in acute myocardial infarction

Nov. 20, 2015

Bayer Schering Pharma presents sGC activators

Nov. 19, 2015

Mayo Clinic describes novel drug candidate for cardiorenal disease

Nov. 11, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Rethinking anorexia: A disorder of mind and metabolism
BioWorld Science
Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...